You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2025

Claims for Patent: 11,779,571

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,779,571

Title:	Methods for treating irritable bowel syndrome (IBS)
Abstract:	The present invention provides new methods and kits for treating IBS; treating IBS in females; treating IBS in older subjects; and treating IBS in non-white subjects.
Inventor(s):	William Forbes, Enoch Bortey
Assignee:	Salix Pharmaceuticals Inc
Application Number:	US17/197,561
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,779,571
Patent Claims:	1. A method of treating bloating associated with diarrhea-predominant irritable bowel syndrome (dIBS) in a female subject, said method comprising administering, 550 mg of rifaximin TID for 14 days to the female subject, thereby treating bloating associated with dIBS in the female subject. 2. The method of claim 1, wherein the treating of bloating comprises a reduction of bloating from baseline symptoms established prior to treatment. 3. The method of claim 2, wherein the reduction of bloating is achieved following 7 days after the administration of rifaximin. 4. The method of claim 2, wherein the reduction of bloating comprises an affirmative response from the subject when asked whether they had a reduction in bloating.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.